Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MnrmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJFMvPj[nLUC1JO69VQ>? NGLPbpZUSU6JRWK=
CAL-51 cell NX7vUXFHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoLhTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?= NV\GTlRRW0GQR1XS
ABC-1 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjxdXBKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjVibl2= M1j5RnNCVkeHUh?=
A2780 cell NXzTTZl2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfWTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVk1KG6P NXLFSGt7W0GQR1XS
ES1 cell NU\qeYd5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWfpd|dWUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc1QSCwTR?= MYDTRW5ITVJ?
HUTU-80 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= M2O1UHNCVkeHUh?=
NCI-H292 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIOySnBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> NI\jZWFUSU6JRWK=
NB69 cell NHG5bWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1XwOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? MYXTRW5ITVJ?
ES8 cell NWL5eVdkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> NHHNeJRUSU6JRWK=
BCPAP cell MoXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoW3TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? M37NN3NCVkeHUh?=
T-24 cell NGTEeXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jTR2lvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? MXjTRW5ITVJ?
EW-16 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? M13aWXNCVkeHUh?=
OVCAR-5 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P MXvTRW5ITVJ?
SF126 cell NYG3d2NMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlHaTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? M{TKcXNCVkeHUh?=
KP-4 cell NFnMXGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG3JI5O MVXTRW5ITVJ?
GAMG cell MlL4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O M1XXc3NCVkeHUh?=
HOS cell M3HSc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHnWYVYUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU{KG6P MmP0V2FPT0WU
CHL-1 cell NVPteG57T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MljuTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFEhdk1? Mo\HV2FPT0WU
AGS cell Ml7NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXW2bWtEUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P NHftNolUSU6JRWK=
MDA-MB-157 cell M{TuW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPwSJNKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O MVvTRW5ITVJ?
HSC-3 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3YSY1KdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= M2XQfXNCVkeHUh?=
CAL-72 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEH1SnlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NI\LXmxUSU6JRWK=
NBsusSR cell NV;kc2x2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHHRW94UW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=> NF6wbHFUSU6JRWK=
ES7 cell NH\KeoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\m[GNKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? M3HlOnNCVkeHUh?=
H-EMC-SS cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3[zSmlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N NGrpcI9USU6JRWK=
NCI-H1703 cell NHv0b2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{LjWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> NWG5NnNtW0GQR1XS
BHT-101 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;kTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?= NGn0XWNUSU6JRWK=
SK-OV-3 cell NX[1bpZYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLIfoxMUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> MkLKV2FPT0WU
EW-24 cell M3jUemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXL3O3ZnUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2= NVXDeXcxW0GQR1XS
PSN1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lki0JI5O MlTHV2FPT0WU
OVCAR-8 cell Ml3tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3pXYJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N M1;odnNCVkeHUh?=
NCI-H1563 cell NV;1UFZXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn35TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF|IH7N MVLTRW5ITVJ?
SW756 cell NH7pSJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? MoPCV2FPT0WU
A375 cell NVnJRXZyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTuTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? NFvDd3FUSU6JRWK=
Ca9-22 cell NWfyWXJLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoS1TY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P MV;TRW5ITVJ?
SW1990 cell MlPFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|Ihdk1? M{nXOHNCVkeHUh?=
ES4 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPncmZuUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM6KG6P NWK0OlA4W0GQR1XS
HCE-T cell MlrhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? M1[2XHNCVkeHUh?=
MOLT-16 cell MkfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfTSo1KdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N NVmzW3VtW0GQR1XS
HSC-4 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64JI5O MV3TRW5ITVJ?
NCI-SNU-1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnyzTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njh4IH7N NIXRW2xUSU6JRWK=
EW-11 cell M37IZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfhfXpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P M3:yRnNCVkeHUh?=
HT-1080 cell M{jvSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P M1XWenNCVkeHUh?=
MES-SA/Dx5 cells NYjXZWQ4S3m2b4TvfIlkcXS7IHHzd4F6 MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|LDDJR|UxRTVibl2= MWmyN|k{Pzl6MR?=
SW1710 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFrLS5JKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= M3nPUHNCVkeHUh?=
EW-1 cell NHPaV2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfIW|hMUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zPCCwTR?= MlXnV2FPT0WU
BV-173 cell NF7wN2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|khdk1? NEjaZ5lUSU6JRWK=
TE-8 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLo[plbUW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OSCwTR?= M4rsOXNCVkeHUh?=
G-401 cell M2PPWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmK5TY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFMhdk1? MXPTRW5ITVJ?
KOSC-2 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFUhdk1? NF7PVJlUSU6JRWK=
HuCCT1 cell NIDxWndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUG0NGFVUW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV{IH7N M4ThN3NCVkeHUh?=
FADU cell NXnZemF[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHXOVWhKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P NX[yV5FOW0GQR1XS
MHH-ES-1 cell NGLZfI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4WxeWlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZ7IH7N MoPiV2FPT0WU
ES3 cell MlnwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTrTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O NWnHOYFXW0GQR1XS
OVCAR-4 cell M3LDPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1XYZWlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDdibl2= M1\kPXNCVkeHUh?=
HD-MY-Z cell NW\YRZFpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P NGm4OlFUSU6JRWK=
human JAR cell MnXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDjO4dKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NVPzW2N7W0GQR1XS
A427 cell NHXyUoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O NV7JW2s{W0GQR1XS
697 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPSSVB4UW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE{KG6P NIfQcnJUSU6JRWK=
OVCAR-3 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnewTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P MnvrV2FPT0WU
human NB14 cell Ml;NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\VRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOlQhdk1? M2fPOnNCVkeHUh?=
GB-1 cell NGK4PYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\ufmlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? M2XOVnNCVkeHUh?=
COR-L105 cell MkHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFS3W45KdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi55NjDuUS=> M2HtUXNCVkeHUh?=
647-V cell M3jLTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HYPWlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1? MV3TRW5ITVJ?
human K5 cell NWq0[ZpZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTxW|hKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NzDuUS=> MnXlV2FPT0WU
DMS-273 cell MofES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF2xUWRKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N MknOV2FPT0WU
UM-UC-3 cell M4LpXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjkTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= NVXTPG9WW0GQR1XS
HEL cell M1SzS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\QVmFKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNFghdk1? NF\FZW5USU6JRWK=
human KU-19-19 cell NX3MUGRWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWTJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xQSCwTR?= MU\TRW5ITVJ?
MC-IXC cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNVchdk1? MoGxV2FPT0WU
human H4 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzjeYRmUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? NFvrZo1USU6JRWK=
NUGC-3 cell MkXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuN|Mhdk1? MlvvV2FPT0WU
CHP-212 cell NWPa[FdZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3HN[WlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2= MVjTRW5ITVJ?
human SW982 cell MnzhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz60OEBvVQ>? NWj5eWVZW0GQR1XS
C-33-A cell NHz2cY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUPZOHZxUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N M3\HO3NCVkeHUh?=
PC-3 cell M3jvNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjBUFFOUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= NYrYcYNZW0GQR1XS
COLO-684 cell NGLkeWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mle4TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= MWfTRW5ITVJ?
SNU-387 cell MoLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvMR|l[UW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=> NFXNTYZUSU6JRWK=
U251 cell NUTvWI9NT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2GyNGlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? MnP1V2FPT0WU
A673 cell NFz2WJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoTOTY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuOkBvVQ>? MYrTRW5ITVJ?
human T47D cell M2LOZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHpTlZKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?= NHLvZ3ZUSU6JRWK=
A549 cell M3PnXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jqXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? M4\PPHNCVkeHUh?=
PC-14 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuO|Mhdk1? NX;ve2IyW0GQR1XS
A704 cell NVHJ[3U5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHX5e|RKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?= M{TXOnNCVkeHUh?=
MCF7 cell NFf0fHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjnPFJKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= M2HYUHNCVkeHUh?=
PC3 cells MYDGeY5kfGmxbjDhd5NigQ>? M{\Sc2lvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0> MXiyNVM1OTZ5NR?=
F-36P cells NWf1PFJYWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEZvM{\QJINmdGy|LDDJR|UxRTBwMkig{txO M4nYflIyOzRzNke1
OCI-AML2 cells M4HNTHBzd2yrZnXyZZRqd25iYYPzZZk> NEDLT2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN NH\pPHozOTN2MU[3OS=>
K562 cells M{j0cnBzd2yrZnXyZZRqd25iYYPzZZk> MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNuIFnDOVA:OThizszN NGP0ZngzOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID